What Basal-Bolus Therapy Means
Basal-bolus therapy is an insulin regimen that mimics normal pancreatic function by combining a long-acting "basal" insulin (given once or twice daily to provide continuous background insulin) with rapid-acting "bolus" insulin (given before meals to cover food intake), plus correction doses for high blood sugars.
Core Components
The basal-bolus approach consists of three distinct elements 1:
1. Basal Insulin (Background)
- Long-acting insulin analog (such as glargine) given once or twice daily
- Provides continuous, "peakless" insulin coverage over 20-24 hours
- Represents approximately 50% of total daily insulin requirement in most children
- Mimics the pancreas's constant baseline insulin secretion
- Must never be stopped, even when the child is not eating 2
2. Bolus Insulin (Mealtime)
- Rapid-acting insulin analog (lispro, aspart, or glulisine) given before each meal
- Covers the carbohydrate intake from food
- Dose calculated using insulin-to-carbohydrate ratios
- Represents the other 50% of total daily insulin 1
- In very young infants with erratic eating, can be given after meals to match actual food consumed 1
3. Correction Insulin
- Additional rapid-acting insulin given when blood glucose is above target
- Administered along with bolus doses or separately every 4-6 hours
- Not the same as "sliding scale" - correction insulin is individualized and considers the patient's insulin sensitivity 3
Why This Matters for a 10-Month-Old with New Type 1 Diabetes
For your infant with persistent hyperglycemia, basal-bolus therapy is the recommended approach even at this young age 1:
Starting Doses
- Total daily insulin: typically 0.3-0.5 units/kg body weight for newly diagnosed patients 4
- Split this 50/50 between basal and bolus components initially
- Very young infants may require minimal basal insulin initially - some may need as little as 10% of total daily dose in the first months 5, 6
Special Considerations for Infants
Critical caveat: In 10-month-old infants, the basal insulin requirement may be much lower than 50% of total daily dose, especially in the first year after diagnosis. Studies show basal insulin may start at only 10% of total daily dose in the third month and gradually increase to 30% by 12 months 6. Some infants with total daily doses under 0.5 units/kg may not require basal insulin at all initially 6.
Practical Implementation
For erratic eaters (common at 10 months):
- Administer rapid-acting insulin after meals rather than before 1
- This allows precise matching of insulin to actual food consumed
- Minimizes hypoglycemia risk when intake is unpredictable
For predictable eaters:
- Give rapid-acting insulin before meals for better postprandial glucose control 1
Advantages Over Other Regimens
The basal-bolus approach has been documented to result in:
- More stable glycemic control compared to intermediate and short-acting insulin regimens 1
- Less hypoglycemia than traditional NPH-based regimens 1
- Better A1C control - studies show improved glycemic control during the first year after diagnosis compared to conventional regimens 7
Monitoring Requirements
This regimen requires frequent blood glucose monitoring - at least 4 tests per day 1. For a 10-month-old who cannot report hypoglycemia symptoms, even more frequent testing at anticipated insulin peaks is necessary 1.
Important Pitfall to Avoid
Do not confuse basal-bolus with "sliding scale insulin" - sliding scale alone (giving insulin only when blood sugar is high without scheduled basal insulin) is inappropriate for type 1 diabetes and will not prevent ketoacidosis 4.
The basal component provides the essential continuous insulin coverage that prevents diabetic ketoacidosis, while the bolus component handles the metabolic demands of feeding - both are necessary for safe management of type 1 diabetes at any age.